Piper Sandler raised the firm’s price target on Scholar Rock (SRRK) to $58 from $51 and keeps an Overweight rating on the shares. The firm is incrementally positive on the shares following a Q4 update that increases its confidence in a relatively near-term apitegromab Biologics License Application resubmission and U.S. launch. Piper continues to believe apitegromab has multiblockbuster potential in spinal muscular atrophy alone, and with U.S. launch finally coming into focus, the firm remains a buyer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock: Positive Regulatory Trajectory and Commercial Readiness for Apitegromab Support Buy Rating and Multi‑Billion‑Dollar SMA Potential
- Scholar Rock price target raised to $70 from $50 at BMO Capital
- Scholar Rock price target raised to $58 from $55 at Citi
- Scholar Rock price target raised to $53 from $52 at Barclays
- Scholar Rock corrects Q4 EPS to (76c), consensus (88c)